NRX Pharmaceuticals, Inc. (NRXP)
1.81
-0.03
(-1.63%)
USD |
NASDAQ |
Feb 20, 13:22
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 53.59M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -27.56% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 127.75 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.4041 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.82% |
Profile
| NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE. |
| URL | http://www.nrxpharma.com |
| Investor Relations URL | https://ir.nrxpharma.com/ |
| HQ State/Province | Delaware |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 17, 2026 (est.) |
| Last Earnings Release | Nov. 17, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE. |
| URL | http://www.nrxpharma.com |
| Investor Relations URL | https://ir.nrxpharma.com/ |
| HQ State/Province | Delaware |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 17, 2026 (est.) |
| Last Earnings Release | Nov. 17, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |